Johnson & Johnson Turned Rybrevant's Survival Win Into a Once-a-Month Injection, With More Planned for Amivantamab

A Survival Curve That Kept Separating

On March 26, 2025, at the European Lung Cancer Congress in Paris, Johnson & Johnson reported the overall survival analysis it had been waiting on since MARIPOSA met its progression-free survival endpoint in October 2023. At a median follow-up of 37.8 months, patients randomized to Rybrevant plus Lazcluze had a hazard ratio for death of 0.75 (95% CI 0.61-0.92, P<0.005) against osimertinib. Median survival had not been reached in the combination arm (95% CI 42.9 months to not reached) and was 36.7 months on osimertinib. At three and a half years, 56% of the combination arm was alive against 44%, and time to symptomatic progression, the interval before lung cancer symptoms return, ran 43.6 months against 29.3. J&J called it the first study to show a statistically significant survival improvement over osimertinib, and projected the median would pass four years.

"The survival curve tells a clear story. RYBREVANT plus LAZCLUZE helps patients live longer, and the benefit keeps growing over time," said Nicolas Girard, MD, PhD, head of medical oncology at Institut Curie and a MARIPOSA investigator. The New England Journal of Medicine published the analysis on Sept. 7, 2025, with James Chih-Hsin Yang of National Taiwan University Cancer Center as lead author. "This is a turning point in how we treat EGFR-mutated lung cancer," Yang said. "Starting with RYBREVANT and LAZCLUZE may prevent common types of resistance and reserves chemotherapy for later lines of therapy, which can help achieve the best possible outcomes."

In a late-breaking analysis at the World Conference on Lung Cancer in Barcelona on Sept. 6, 2025, MET amplification appeared in 3% of patients on the combination and 13% on osimertinib (P=0.002), and secondary EGFR mutations such as C797S in 1% against 8% (P=0.01). Among patients who stayed on the combination at least six months, 2% developed MET amplification and none developed C797S. "We now have a body of evidence that suggests TKI monotherapy is no longer enough in the first-line treatment of EGFR-mutated lung cancer," said Sanjay Popat, FRCP, PhD, of the Royal Marsden Hospital. The 501 participants who identified as Asian, analyzed separately at ESMO Asia on Dec. 8, 2025, tracked the full 1,074-patient trial, with a hazard ratio of 0.74 and 61% alive at three years against 53%.

Danny Nguyen's Once-a-Month Injection

MARIPOSA's regimen asked something of patients in return, since in the trial rash occurred in 86% of the combination arm, infusion-related reactions in 63% and venous thromboembolism in 36%, most of it in the first four months, and Rybrevant's label calls for prophylactic anticoagulation over that period. J&J's response has been to engineer the burden down. The Phase 2 COCOON trial of a proactive dermatologic regimen, first presented at ELCC 2025, met its primary endpoint for preventing skin reactions, and the label now recommends emollients and prophylactic measures from the first dose.

The larger change came on Dec. 17, 2025, when the FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneous formulation built on Halozyme's ENHANZE technology, across all four Rybrevant indications. In the Phase 3 PALOMA-3 trial, the injection matched IV amivantamab on both co-primary pharmacokinetic endpoints, took about five minutes in place of several hours, cut administration-related reactions from 66% to 13% and lowered venous thromboembolism from 18% to 11%. J&J also reported a nominal overall survival hazard ratio of 0.62 favoring the subcutaneous arm (95% CI 0.42-0.92), an observation from a trial designed to test pharmacokinetics that the company describes as supportive.

Two months later, on Feb. 17, 2026, the agency approved a monthly schedule. Patients on Rybrevant Faspro plus Lazcluze can move from every-two-week to every-four-week injections from Week 5. In the PALOMA-2 cohort that supported the change, administration-related reactions were 12% against 13% with biweekly dosing, venous thromboembolic events 13% against 11%, and 8% of patients stopped amivantamab for treatment-related adverse events. "A monthly dosing schedule offers patients convenience without sacrificing efficacy," said Danny Nguyen, MD, of City of Hope, principal investigator for PALOMA-3 and MARIPOSA. "With a flexible schedule that reduces time in the clinic, patients may be able to stay on therapy longer and free up time to focus on the moments that matter most." Mahadi Baig, MD, J&J's vice president of US medical affairs, called the injection "the simplest and fastest combination therapy for patients with EGFR-mutated non-small cell lung cancer."

$289 Million and Climbing

Rybrevant and Lazcluze brought in $289 million in the quarter ended June 28, 2026, up 60.8% from $179 million a year earlier, with $190 million in the United States and $99 million elsewhere, according to J&J's 10-Q. First-half sales were $546 million against $320 million. The company named the pair, with Darzalex, Carvykti and Tecvayli, as the drivers of 16.1% operational growth in oncology, raised full-year guidance to $101.1 billion in sales, and singled out the head and neck data as one of the quarter's pipeline events. The context for that growth is a target Chief Executive Joaquin Duato set on the July 2025 earnings call, as reported by BioSpace: $50 billion in oncology sales by 2030.

The NCCN lists Rybrevant plus Lazcluze as a Category 1 first-line option for exon 19 deletion and L858R disease, Rybrevant plus chemotherapy as Category 1 after osimertinib on the strength of MARIPOSA-2, where median overall survival at the second interim analysis ran 17.7 months against 15.3 for chemotherapy alone (HR 0.73), and Rybrevant plus chemotherapy as Category 1 first-line treatment for exon 20 insertions.

Forty-One Months in Atypical EGFR Disease

Atypical EGFR mutations account for roughly 10 to 20% of EGFR-mutated lung cancer and have historically done worse on single-agent TKIs, with median survival under two years. On May 29, 2026, at ASCO, J&J reported Cohort C of the Phase 1/1b CHRYSALIS-2 study: 49 previously untreated patients, most often carrying G719X, given IV Rybrevant plus Lazcluze. The response rate, reported earlier, was 57%. Median overall survival reached 41.0 months (95% CI 27.7 to not estimable) at 31.3 months of follow-up, 55% of patients were alive at three years and 46% at four, and 41% stayed on Rybrevant for two years or longer.

"For patients with non-small cell lung cancer harboring atypical EGFR-mutations, first-line treatment decisions are often clouded by uncertainty regarding the efficacy of currently available EGFR tyrosine kinase inhibitors," said Joel Neal, MD, PhD, of Stanford Medicine, the study's principal investigator. "The responses we've seen in this trial suggest the potential for more durable disease control, and the overall survival data reinforce that picture." Yusri Elsayed, MD, PhD, J&J's global therapeutic area head for oncology, put it in the company's terms: "With strong outcomes across all known EGFR mutations, this approach is raising the bar for what first-line treatment can achieve."

Barbara Burtness and the Head and Neck Filing

On May 31, 2026, two days after the atypical-mutation data, J&J presented Cohort 1 of OrigAMI-4: 102 patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with immunotherapy and platinum chemotherapy, HPV-positive oropharyngeal cancer excluded, given subcutaneous amivantamab alone every three weeks after a loading dose. The confirmed response rate by blinded central review was 42% (95% CI 32-52), including complete responses in 15% of patients, in a setting where J&J notes response rates rarely exceed 24%. Median progression-free survival was 6.8 months and median overall survival 12.5 months, with the median duration of response not reached at 11.8 months of follow-up.

"The high response seen with subcutaneous amivantamab on its own, including more than one-third of responders achieving complete responses, and the durability of those responses, suggests it has the potential to meaningfully improve expectations for these patients," said Barbara Burtness, MD, of Yale Cancer Center. The FDA granted the supplemental application Priority Review on July 30, 2026, after an earlier Breakthrough Therapy Designation, which puts the first amivantamab indication outside lung cancer on a six-month clock.

Halda's Oral Chemistry Comes Next

J&J completed its $3.05 billion cash acquisition of Halda Therapeutics on Dec. 26, 2025. Halda's RIPTAC molecules are bifunctional small molecules that bind a tumor-specific protein and a protein essential to cell survival at the same time, a design meant to kill cancer cells that have found ways around conventional inhibition. The lead, HLD-0915, is a once-daily oral therapy in metastatic castration-resistant prostate cancer, and J&J said the deal also brought "several earlier candidates for breast, lung and multiple other tumor types." BioSpace's account of the deal names an HR-positive breast cancer program and a lung cancer asset among them. "Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond," said John C. Reed, MD, PhD, J&J's executive vice president for Innovative Medicine R&D. The second-quarter 10-Q names only HLD-0915, so the lung program's timeline is the company's to announce.

Why This Matters to the APO|APE Reader

The NCCN guideline that carries these regimens also states a preference for next-generation sequencing over PCR for detecting EGFR exon 20 insertions, so the first-line decision now depends on a complete EGFR call at diagnosis, atypical variants included, and CHRYSALIS-2 gives the molecular lab a survival number to attach to a G719X or S768X report. At progression, the MARIPOSA resistance analysis changes what a repeat biopsy or ctDNA panel is likely to find after the combination, with MET amplification and C797S both rare, which shifts the post-progression question toward histologic transformation and other mechanisms. The five-minute injection moves the drug out of the infusion chair, and monthly dosing from Week 5 cuts a first-line patient's visits by half. The next dates are the FDA's action on the head and neck application, due within the six months that began July 30, and WCLC 2026 in Seoul on Sept. 12-15.